Inovio Pharmaceuticals provided a preliminary, unaudited estimate that its cash, cash equivalents, and short-term investments totaled approximately $48.4 million as of September 30, 2026. This figure is based on management estimates prior to the completion of financial closing procedures for the quarter ended September 30, 2026, and has not been audited or reviewed by Ernst & Young LLP. The company cautioned that actual results may differ materially from these preliminary figures due to changes in assumptions or internal control reviews. Inovio Pharmaceuticals operates in the biotechnology industry, focusing on the development of DNA-based vaccines and immunotherapies.
